Logo

EMA's CHMP Recommends Compassionate Use of Gilead's Remdesivir for COVID-19

Share this
EMA's CHMP Recommends Compassionate Use of Gilead's Remdesivir for COVID-19

EMA's CHMP Recommends Compassionate Use of Gilead's Remdesivir for COVID-19

Shots:

  • On Apr 02- 2020- EMA’s CHMP has recommended Gilead’s Remdesivir to be used for treating COVID-19 in compassionate use programmes in the EU
  • Compassionate use programmes are intended to provide patients access to therapies that are under development and have not yet received a marketing authorization. The CHMP encourages Gilead to make remdesivir available in a transparent way to those Member States wishing to take part in international clinical studies or treat patients in compassionate use programmes
  • Estonia- Greece- the Netherlands and Romania requested CHMP’s opinion on the conditions under which early access to Remdesivir via compassionate use could be offered to patients with COVID-19

Click here ­to­ read full press release/ article 

 Ref: EMA | Image: Gilead


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions